Newswire (Published: Tuesday, May 2, 2017, Received: Thursday, April 27, 2017, 10:59:46 PM CDT)

Word Count: 548

New Prostate Cancer Study Findings Recently Were Reported by Researchers at New York University Langone Medical Center (Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting from New York City, New York, by NewsRx journalists, research stated, "To examine the use of the Prostate Health Index (PHI) as a continuous variable in multivariable risk assessment for aggressive prostate cancer in a large multicentre US study. The study population included 728 men, with prostate-specific antigen (PSA) levels of 2-10 ng/mL and a negative digital rectal examination, enrolled in a prospective, multi-site early detection trial."

Financial supporters for this research include Beckman Coulter Incorporated, Laura and Isaac Perlmutter Cancer Center at New York University, Louis Feil Charitable Lead Trust, National Institutes of Health/National Cancer Institute (NIH/NCI) Johns Hopkins Prostate SPORE, Early Detection Research Network NIH/NCI, Urological Research Foundation, Northwestern-University of Chicago-NorthShore University Prostate SPORE, Robert H. Lurie Comprehensive Cancer Center (see also Oncology - Prostate Cancer).

The news correspondents obtained a quote from the research from New York University Langone Medical Center, "The primary endpoint was aggressive prostate cancer, defined as biopsy Gleason score greater than or equal to7. First, we evaluated whether the addition of PHI improves the performance of currently available risk calculators (the Prostate Cancer Prevention Trial [PCPT] and European Randomised Study of Screening for Prostate Cancer [ERSPC] risk calculators). We also designed and internally validated a new PHI-based multivariable predictive model, and created a nomogram. Of 728 men undergoing biopsy, 118 (16.2%) had aggressive prostate cancer. The PHI predicted the risk of aggressive prostate cancer across the spectrum of values. Adding PHI significantly improved the predictive accuracy of the PCPT and ERSPC risk calculators for aggressive disease. A new model was created using age, previous biopsy, prostate volume, PSA and PHI, with an area under the curve of 0.746. The bootstrap-corrected model showed good calibration with observed risk for aggressive prostate cancer and had net benefit on decision-curve analysis."

According to the news reporters, the research concluded: "Using PHI as part of multivariable risk assessment leads to a significant improvement in the detection of aggressive prostate cancer, potentially reducing harms from unnecessary prostate biopsy and overdiagnosis."

For more information on this research see: Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. Bju International, 2016;():. (Wiley-Blackwell -; Bju International -

Our news journalists report that additional information may be obtained by contacting S. Loeb, Dept. of Urology and Population Health, New York University Langone Medical Center, New York, NY, United States. Additional authors for this research include S.S. Shin, D.L. Broyles, J.T. Wei, M. Sanda, G. Klee, A.W. Partin, L. Sokoll, D.W. Chan, C.H. Bangma, R.H. van Schaik, K.M. Slawin, L.S. Marks and W.J Catalona.

Keywords for this news article include: Oncology, New York City, United States, Prostatic Neoplasms, Risk and Prevention, North and Central America, Metastatic Prostate Cancer.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Beckman Coulter Inc.
Danaher Corporation
New York University


      Healthcare Facilities
            Cancer Centers


Central America
North America
United States
New York
New York City


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices
Politics and Government
      Government Agencies (U.S.)
            Department of Health and Human Services
                  National Institutes of Health